{"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"OTHER","pValue":"0.1705","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.863","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.359","groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","paramType":"pairwise GMR","paramValue":"1.083"},{"ciLowerLimit":"0.719","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.132","groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"pairwise GMR","paramValue":"0.902"},{"ciLowerLimit":"0.945","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.554","groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"pairwise GMR","paramValue":"1.212"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"8250"},{"groupId":"OG001","spread":"0.39","value":"16600"},{"groupId":"OG002","spread":"0.34","value":"18300"},{"groupId":"OG003","spread":"0.31","value":"29700"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"AUC0-tau was defined as the area under the concentration-time curve from dosing (time 0) of INCB001158 to the end of the dosing period.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose","title":"AUC0-tau of INCB001158 Following Multiple Escalating Doses for Part 1A","type":"SECONDARY","unitOfMeasure":"hours x ng/mL"}